FDA Moves to Register Overseas Tobacco Makers
Published Date: 6/29/2026
Proposed Rule
Summary
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
Analyzed Economic Effects
7 provisions identified: 1 benefits, 6 costs, 0 mixed.
Foreign Makers Must Register and List
If finalized, owners and operators of foreign establishments that manufacture, prepare, compound, or process tobacco products sold in or offered for import into the United States would have to register their establishments and list their products with FDA. The proposal explicitly extends current registration and listing requirements to foreign establishments under proposed 21 CFR 1108 and would bring parity between domestic and foreign owners/operators.
Foreign Establishments Subject to FDA Inspections
The proposal would make registered foreign establishments subject to FDA inspections under sections 905(g) and 905(h) of the FD&C Act. FDA states that registered foreign establishments would be subject to inspection in support of enforcement and premarket review activities.
More Entities Count as 'Manufacturers'
The proposed rule clarifies that the term 'manufacture' includes specification developers, third-party manufacturers, bulk tobacco product manufacturers, and repackagers/relabelers. As a result, these types of entities would be required to register and list products under the proposed 21 CFR 1108 requirements.
Noncompliance Can Trigger Enforcement Actions
The document states that failure to register, to provide required product listing information, or to provide required notices can constitute prohibited acts under section 301 of the FD&C Act and that violations related to establishment registration and product listing are subject to regulatory action, including civil money penalties, seizure, and injunction.
Electronic Submission Required (Waivers Possible)
The proposed rule would generally require electronic submission of establishment registration and tobacco product listing information, unless FDA grants a waiver. FDA says electronic submission would be used by all registrants and would further the Government Paperwork Elimination Act goals.
New Recordkeeping Requirements for Listed Products
The proposed rule would require owners or operators to maintain a historical file of consumer information, labeling, and advertisements for all tobacco products listed, and to keep records about the distribution of free samples of smokeless tobacco products. These recordkeeping requirements are proposed under sections 905 and 909 of the FD&C Act.
Agency Estimates of Annualized Costs
FDA estimates 20-year annualized total costs to domestic and foreign establishments and FDA would range from $6.80 million to $26.55 million, with a primary estimate of $15.57 million at a 7% discount rate. FDA reports domestic-establishment costs of $0.013 million (primary estimate) and foreign-establishment costs of $0.37 million (primary estimate), with FDA shouldering about 97.5% of total costs in the primary estimate.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-16452, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products." This guidance outlines the recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of new drug or biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This guidance finalizes the draft guidance of the same title issued on September 22, 2023.
2026-16536, Kremers Urban Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets
The Food and Drug Administration (FDA or the Agency) is announcing a formal evidentiary public hearing on the proposal to withdraw approval of the abbreviated new drug application (ANDA) 091695, submitted by Kremers Urban Pharmaceuticals, Inc. (Kremers) for methylphenidate hydrochloride extended-release tablets. On October 18, 2016, the Director of FDA's Center for Drug Evaluation and Research (CDER) published a notice of opportunity for hearing on a proposal to withdraw approval of ANDA 091695. Kremers submitted a timely request for hearing on that proposal. This notice of hearing provides factual and legal information concerning CDER's proposal to withdraw approval of ANDA 091695 and identifies the factual issues that will be the subject of the evidentiary hearing.
2026-16420, Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
2026-16353, Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. GDUFA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to authorize FDA to assess and collect fees to support human generic drug activities. The current legislative authority for GDUFA expires at the end of September 2027. At that time, new legislation will be required for FDA to continue to assess and collect generic drug user fees for future fiscal years. The FD&C Act directs FDA, following negotiations with the regulated industry and periodic consultations with other stakeholders, to present recommendations for reauthorization of the GDUFA program to the relevant Congressional committees, publish the recommendations in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.
Previous / Next Documents
Previous: 2026-13034, Airworthiness Directives; Airbus Helicopters Deutschland GmbH (AHD) Helicopters
If you own or operate certain Airbus Helicopters Deutschland models, listen up! The FAA wants you to regularly check your tail rotor blades for cracks caused by corrosion and replace any damaged parts to keep flying safe. Comments on this new rule are open until August 13, 2026, so get ready to inspect and possibly spend some bucks to keep your chopper in top shape.
Next: 2026-13054, Fisheries Off West Coast States; Coastal Pelagic Species Fisheries; Annual Specifications; 2026-2027 Annual Specifications and Management Measures for Pacific Sardine
Starting July 1, 2026, most commercial fishing for Pacific sardines off Washington, Oregon, and California will be paused to help the sardine population bounce back. Only limited fishing for live bait, small catches, or special permits will be allowed. This plan sets clear catch limits to protect the fish and supports a healthier ocean and fishing future.